Aktienanalyse zu cbdMD Inc (YCBD)YCBDcbdMD Inc

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms. It operates in the Healthcare sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Considering the current price of $0.42, the RSI at 64.31 indicates that the stock is approaching overbought territory, yet it has shown a strong recent performance with a 5-day change of +8.62%. The forward P/E ratio is extremely high at 714.29, indicating that while the stock is currently trading at a low price, future earnings growth is expected to be significant. The main risk is the company's ongoing net losses, with a net income of -$1,198,233 reported in Q3 2026, which could impact future profitability.